



(11) **EP 1 900 753 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
09.04.2008 Bulletin 2008/15

(43) Date of publication A2:
19.03.2008 Bulletin 2008/12

(21) Application number: **07014054.6**

(22) Date of filing: **07.11.2003**

(51) Int Cl.:
C07K 16/42 (2006.01) **C07K 16/28** (2006.01)
C12N 15/13 (2006.01) **A61K 39/395** (2006.01)
A61P 35/00 (2006.01)

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**
Designated Extension States:
AL LT LV MK

(30) Priority: **08.11.2002 US 425073 P**
08.11.2002 US 425063 P
10.01.2003 EP 03447005
23.06.2003 WOPCT/EP03/06581
08.07.2003 WOPCT/EP03/07313

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
03775004.9 / 1 558 650

(71) Applicant: **Ablynx N.V.**
9052 Ghent-Zwijnaarde (BE)

(72) Inventors:
• **Silence, Karen**
3090 Overijse (BE)
• **Vaeck, Mark**
1981 Hofstade (BE)
• **Van Bergen En Henegouwen, Paul P., M., P.**
3584 GE Utrecht (NL)

(74) Representative: **HOFFMANN EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **Method of administering therapeutic polypeptides, and polypeptides therefor**

(57) The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to

the said therapeutic molecules. The invention further relates to a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.

EP 1 900 753 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 63 of the European Patent Convention EP 07 01 4054
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	MURUGANANDAM ET AL: "Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium" THE FASEB JOURNAL, 28 December 2001 (2001-12-28), pages 1-22, XP002469469 Retrieved from the Internet: URL:www.fasebj.org/cgi/reprint/01-0343fjev 1> [retrieved on 2008-02-18] * See page 1 (Abstract); page 2 (third paragraph); page 10 (third paragraph); page 11 (penultimate paragraph) *	1-3,5-22	INV. C07K16/42 C07K16/28 C12N15/13 A61K39/395 A61P35/00
Y	LORIMER: "Mutant epidermal growth factor receptors as targets for cancer therapy" CURRENT CANCER DRUG TARGETS, vol. 2, June 2002 (2002-06), pages 91-102, XP008088776 * See the whole document *	1-3,5-22	
			TECHNICAL FIELDS SEARCHED (IPC)
			C07K C12N A61K A61P
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
Berlin		21 February 2008	Korsner, Sven-Erik
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

17

EPO FORM 1503 03.82 (P04E07)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 07 01 4054

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (IPC)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	POUL ET AL: "Selection of tumor-specific internalizing human antibodies from phage libraries" JOURNAL OF MOLECULAR BIOLOGY, vol. 301, 2000, pages 1149-1161, XP000984954 * See pages 1149-1150 (Introduction) * -----	1-3,5-22	TECHNICAL FIELDS SEARCHED (IPC)
Y	CORTEZ-RETAMOZO ET AL: "Efficient tumor targeting by single-domain antibody fragments of camels" INTERNATIONAL JOURNAL OF CANCER, vol. 98, March 2002 (2002-03), pages 456-462, XP002248403 * See page 456 (Introduction) and pages 459-461 (Discussion) * -----	1-3,5-22	
Y	WIKSTRAND ET AL: "Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas" CANCER RESEARCH, vol. 55, 1995, pages 3140-3148, XP002074673 * See page 3140 (Abstract) * -----	1-3,5-22	
A	CONRATH ET AL: "Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, 2001, pages 7346-7350, XP002248402 * See page 7346 (Abstract) * ----- -/--	1-22	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 07 01 4054

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (IPC)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
E	<p>WO 2004/081026 A (DOMANTIS LIMITED) 23 September 2004 (2004-09-23) * See page 2 (camelid antibodies), page 3 (PEG), page 5 (TNF-alpha), pages 83-84 (EVQLL.....VTVSS), and page 96 (internalizing binding receptor); see priority documents 1-2 *</p> <p style="text-align: center;">-----</p>	1-3,5-22	
			TECHNICAL FIELDS SEARCHED (IPC)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 07 01 4054

Although Claims 12-16 are directed to a method of treatment of the human body, the search has been carried out and been based on the alleged effects of the compositions.

21-02-2008

EPO FORM P0459

6